Andrew Fenny

Andrew brings over 20 years of diverse experience in life sciences to his role as CCO at SK pharmteco. He started his career at Avecia, a CMO specializing in the development and manufacture of biologics. In this role, he managed multi-disciplinary program teams comprising program managers, technologists, scientists, and engineers to ensure the delivery of services in line with customer expectations. Following the acquisition of Avecia by MSD and subsequently by FUJIFILM Diosynth Biotechnologies in 2012, Andrew eventually became the Chief Business Officer for FUJIFILM Diosynth Biotechnologies in 2018. FUJIFILM Diosynth Biotechnologies provides end-to-end development and manufacturing services in biologics, gene therapy, and cell therapy. Andrew holds a BS in Molecular & Cellular Biology from the University of Huddersfield, UK.